Genetic factors in the treatment of bronchial asthma.
Owing to the recent vast progress in analytical tools and procedures to elucidate the relationship between genes and diseases, many candidate genes leading to the development of bronchial asthma have been reported. However, the quantitative phenotypes of asthma, such as decrease in forced expiratory volume in the first second, serum hyper-IgE, bronchial hyperresponsiveness and blood hyper-eosinophilia, do not represent this disease completely. On the other hand, eosinophilic inflammation of the bronchial mucosa represents accurately the feature of bronchial asthma, although accurate quantification of its status is difficult. While the production of interleukin (IL)-5 in peripheral CD4(+) T cells probably correlates with eosinophilic inflammation of the airway, the effectiveness of anti-IL-5 antibody for the treatment of bronchial asthma is controversial. Since intervention with asthma-causing gene products may not be sufficient for the treatment of this disease, identification of therapy-responsive genes should become more important in the near future.
Kaminuma
Osamu
O
The Tokyo Metropolitan Institute of Medical Science, Department of Allergy and Immunology, 3-18-22, Honkomagome, Bunkyo-ku, Tokyo 113-8613, Japan. kaminuma@rinshoken.or.jp
Suko
Matsunobu
M
Mori
Akio
A